CDK2 and cancer: According to the limited number of previous studies, CDK2 inhibition is associated with anti‐tumor effect of some anti‐cancer candidate drugs in ATC, including G1‐phase cell cycle arrest.[23, 24, 25] In our study, CDK2 demonstrated a useful biomarker for ATC, which overexpressed in ATC compared with normal thyroid tissues and DTC, and showed the significant correlations with no response to lenvatinib, disease progression and decease event in ATC patients.